Biotech & Life Sciences
How Epicrispr are leading the first epigenetic editing trial for muscular dystrophy
“We can regulate any gene, anywhere,” says CEO Dr. Amber Salzman, whose Epicrispr team is pioneering epigenetic editing - a precise, non-cutting approach - to transform neuromuscular disease treatment through durable, targeted control of gene activity.
Four years of progression-free survival: Nuvation Bio’s new standard in lung cancer
With a median progression-free survival nearing four years in ROS1 lung cancer, Nuvation Bio’s breakthrough therapy signals a turning point for precision oncology - validating Dr. David Hung’s patient-first vision.
FDA approvals - September 2025
September’s FDA approvals signaled shifting rules in biopharma - faster launches, smarter formulations, and bold plays from rising innovators and the familiar giants.
From stealth to spotlight: with $70m Series A, ‘total allergic control’ is Excellergy's goal
Backed by $70 million in Series A funding, Excellergy emerges from stealth with a mission to lead a new era in immunology - targeting the full IgE pathway to redefine how allergic diseases are treated.
New CEO of Kindbody David Stern is in the business of building families
“Fifteen to twenty years ago, a woman under 35 had a 20% chance of live birth per IVF cycle. At Kindbody, today, it’s greater than 50%,” David Stern credits lab innovation and AI for rewriting fertility’s odds.
A Legend in the making: how Ying Huang is scaling CAR-T to global markets
“After just one single infusion, about a third of patients remained in remission for five years. Some physicians even called it a functional cure,” Ying Huang underlines why CARVYKTI is reshaping expectations in oncology.
From sickness to prevention: How welfare cuts risk undermining the UK's 10-Year Health Plan
“Preventative care spending fell from 14.1% to just 5.2% of Government healthcare spending.” Ben Phillips warns that welfare reforms could widen existing health gaps.
Moloch and Medicine: why good intentions built a broken system, and why CGT might fix it all (sort of)
Anis Fahandej-Sadi breaks down the big problems with current incentive structures
Breaking the bottleneck: why Oklo’s bet on Atomic Alchemy could change cancer care
"Some companies can’t even finish clinical trials because they can’t get enough material. It all comes down to the supply chain,” Thomas Eiden underscores why secure isotope access is critical for next-generation cancer treatment.
When is JPM Week 2026?
All the details on when the 44th annual J.P. Morgan Healthcare Conference takes place!
Finding balance in the noise
"Almost a third of over-65s will fall each year", but could nGVS represent a discreet tool against imbalance?
Sick enough: the silent struggles of sub-clinical illness in modern medicine
To live in the grey zone of sub-clinical pathology is to be unwell enough to hurt, but not enough to be heard.
In the Company of Shadows: Love, Labour, and the Long Way Through
First-generation medical students carry two textbooks - one devoted to anatomy, the other towards cultivating resilience.
Gut Feelings: Harnessing the Gut Microbiome to Manage Anxiety in Primary Care
Trillions of microbes inside us are not mere bystanders, but quiet architects of our moods.
The rise of Chinese pharmaceuticals and biotech
"These projects are more than acts of goodwill," China's Health Silk Road is as much about soft power as it is about medicine.